|Mr. Kenneth L. Waggoner||Chairman, CEO, Pres, Gen. Counsel & Sec.||316.67k||N/A||1948|
|Mr. Carlos A. Trujillo CPA, CPA||CFO & Director||250k||N/A||1958|
|Dr. Gerald W. Crabtree||Chief Scientific Officer & Director||109.67k||N/A||1941|
|Dr. Jose L. Iglesias||Consulting Chief Medical Officer||N/A||N/A||N/A|
|Dr. Hans-Peter Hammes||Member of Medical & Scientific Advisory Board and Consultant||N/A||N/A||N/A|
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.
PharmaCyte Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.